Logo image of IMCC

IM CANNABIS CORP (IMCC) Stock Fundamental Analysis

NASDAQ:IMCC - Nasdaq - CA44969Q4060 - Common Stock - Currency: USD

2.16  -0.02 (-0.92%)

After market: 2.18 +0.02 (+0.93%)

Fundamental Rating

2

Overall IMCC gets a fundamental rating of 2 out of 10. We evaluated IMCC against 194 industry peers in the Pharmaceuticals industry. IMCC may be in some trouble as it scores bad on both profitability and health. IMCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMCC had negative earnings in the past year.
In the past year IMCC had a positive cash flow from operations.
IMCC had negative earnings in each of the past 5 years.
In the past 5 years IMCC always reported negative operating cash flow.
IMCC Yearly Net Income VS EBIT VS OCF VS FCFIMCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

IMCC has a Return On Assets of -28.82%. This is comparable to the rest of the industry: IMCC outperforms 54.59% of its industry peers.
The Return On Equity of IMCC (-216.04%) is worse than 72.43% of its industry peers.
Industry RankSector Rank
ROA -28.82%
ROE -216.04%
ROIC N/A
ROA(3y)-112.32%
ROA(5y)-148.76%
ROE(3y)-302.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMCC Yearly ROA, ROE, ROICIMCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

1.3 Margins

IMCC has a Gross Margin (12.87%) which is in line with its industry peers.
IMCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMCC Yearly Profit, Operating, Gross MarginsIMCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMCC has been increased compared to 1 year ago.
The number of shares outstanding for IMCC has been increased compared to 5 years ago.
Compared to 1 year ago, IMCC has a worse debt to assets ratio.
IMCC Yearly Shares OutstandingIMCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
IMCC Yearly Total Debt VS Total AssetsIMCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

IMCC has an Altman-Z score of -8.03. This is a bad value and indicates that IMCC is not financially healthy and even has some risk of bankruptcy.
IMCC has a Altman-Z score of -8.03. This is in the lower half of the industry: IMCC underperforms 69.19% of its industry peers.
IMCC has a debt to FCF ratio of 5.69. This is a neutral value as IMCC would need 5.69 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 5.69, IMCC belongs to the best of the industry, outperforming 84.32% of the companies in the same industry.
A Debt/Equity ratio of 2.24 is on the high side and indicates that IMCC has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.24, IMCC is doing worse than 80.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.24
Debt/FCF 5.69
Altman-Z -8.03
ROIC/WACCN/A
WACC12.22%
IMCC Yearly LT Debt VS Equity VS FCFIMCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

IMCC has a Current Ratio of 0.70. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC has a worse Current ratio (0.70) than 95.68% of its industry peers.
IMCC has a Quick Ratio of 0.70. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC has a worse Quick ratio (0.52) than 95.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.52
IMCC Yearly Current Assets VS Current LiabilitesIMCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for IMCC have decreased strongly by -172.51% in the last year.
The Revenue has decreased by -2.23% in the past year.
Measured over the past years, IMCC shows a very strong growth in Revenue. The Revenue has been growing by 45.36% on average per year.
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-156.25%
Revenue 1Y (TTM)-2.23%
Revenue growth 3Y45.36%
Revenue growth 5YN/A
Sales Q2Q%12.23%

3.2 Future

IMCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.67% yearly.
IMCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.34% yearly.
EPS Next Y-314.48%
EPS Next 2Y32.44%
EPS Next 3Y20.67%
EPS Next 5YN/A
Revenue Next Year19.16%
Revenue Next 2Y25.82%
Revenue Next 3Y21.34%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IMCC Yearly Revenue VS EstimatesIMCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IMCC Yearly EPS VS EstimatesIMCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMCC. In the last year negative earnings were reported.
Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCC Price Earnings VS Forward Price EarningsIMCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

98.92% of the companies in the same industry are more expensive than IMCC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.45
EV/EBITDA N/A
IMCC Per share dataIMCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as IMCC's earnings are expected to grow with 20.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.44%
EPS Next 3Y20.67%

More info and screens

0

5. Dividend

5.1 Amount

IMCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IM CANNABIS CORP

NASDAQ:IMCC (2/21/2025, 8:00:01 PM)

After market: 2.18 +0.02 (+0.93%)

2.16

-0.02 (-0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-26 2025-03-26/bmo
Inst Owners3.91%
Inst Owner Change-100%
Ins Owners39.79%
Ins Owner ChangeN/A
Market Cap6.67M
Analysts82.86
Price TargetN/A
Short Float %0.95%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.16%
Min EPS beat(2)71.55%
Max EPS beat(2)80.78%
EPS beat(4)2
Avg EPS beat(4)0.03%
Min EPS beat(4)-105.88%
Max EPS beat(4)80.78%
EPS beat(8)4
Avg EPS beat(8)-51.04%
EPS beat(12)4
Avg EPS beat(12)-431.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-12.75%
Max Revenue beat(2)9.9%
Revenue beat(4)3
Avg Revenue beat(4)2.27%
Min Revenue beat(4)-12.75%
Max Revenue beat(4)11.57%
Revenue beat(8)3
Avg Revenue beat(8)-1.99%
Revenue beat(12)4
Avg Revenue beat(12)-6.98%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.18
P/FCF 3.45
P/OCF 3.26
P/B 1.59
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.28
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)0.63
FCFY29.02%
OCF(TTM)0.66
OCFY30.65%
SpS11.72
BVpS1.36
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.82%
ROE -216.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.87%
FCFM 5.35%
ROA(3y)-112.32%
ROA(5y)-148.76%
ROE(3y)-302.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 2.24
Debt/FCF 5.69
Debt/EBITDA N/A
Cap/Depr 6.49%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.52
Altman-Z -8.03
F-Score5
WACC12.22%
ROIC/WACCN/A
Cap/Depr(3y)40.3%
Cap/Depr(5y)133.94%
Cap/Sales(3y)5.85%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-172.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-156.25%
EPS Next Y-314.48%
EPS Next 2Y32.44%
EPS Next 3Y20.67%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.23%
Revenue growth 3Y45.36%
Revenue growth 5YN/A
Sales Q2Q%12.23%
Revenue Next Year19.16%
Revenue Next 2Y25.82%
Revenue Next 3Y21.34%
Revenue Next 5YN/A
EBIT growth 1Y32.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y133.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y154.17%
OCF growth 3YN/A
OCF growth 5YN/A